Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,940 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma.
Shariat SF, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Otto W, Karakiewicz PI, Ficarra V, Novara G. Shariat SF, et al. Among authors: baba s. World J Urol. 2011 Aug;29(4):481-6. doi: 10.1007/s00345-010-0594-7. Epub 2010 Oct 1. World J Urol. 2011. PMID: 20886219
Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study.
Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martínez-Salamanca JI, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, Shariat SF. Novara G, et al. Among authors: baba s. Eur Urol. 2010 Jun;57(6):1064-71. doi: 10.1016/j.eururo.2009.12.029. Epub 2010 Jan 6. Eur Urol. 2010. PMID: 20071073
Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients.
Otto W, Shariat SF, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, Martignoni G, Walton TJ, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Burger M, Karakiewicz PI, Ficarra V, Novara G. Otto W, et al. Among authors: baba s. World J Urol. 2011 Aug;29(4):487-94. doi: 10.1007/s00345-011-0645-8. Epub 2011 Jan 20. World J Urol. 2011. PMID: 21249372
Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma.
Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, Shariat SF. Fajkovic H, et al. Among authors: baba s. World J Urol. 2013 Feb;31(1):5-11. doi: 10.1007/s00345-012-0939-5. Epub 2012 Sep 26. World J Urol. 2013. PMID: 23011256
Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma.
Fritsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, Sircar K, Zattoni F, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Otto W, Wieland WF, Karakiewicz PI, Ficarra V, Hartmann A, Shariat SF. Fritsche HM, et al. Among authors: baba s. Urol Oncol. 2012 Sep;30(5):666-72. doi: 10.1016/j.urolonc.2010.07.010. Epub 2010 Oct 8. Urol Oncol. 2012. PMID: 20933445
Immunohistochemical biomarkers for bladder cancer prognosis.
Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H, Sun M, Karakiewicz PI, Scherr DS, Shariat SF. Matsushita K, et al. Among authors: baba s. Int J Urol. 2011 Sep;18(9):616-29. doi: 10.1111/j.1442-2042.2011.02809.x. Epub 2011 Jul 20. Int J Urol. 2011. PMID: 21771101
2,940 results